000			01487 a2200421 4500
005			20250517143039.0
264		0	_c20170427
008			201704s 0 0 eng d
022			_a1873-2763
024	7		_a10.1016/j.bone.2017.03.006 _2doi
040			_aNLM _beng _cNLM
100	1		_aLeder, Benjamin Z
245	0	0	_aImportance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up). _h[electronic resource]
260			_bBone _cMay 2017
300			_a54-58 p. _bdigital
500			_aPublication Type: Clinical Trial; Journal Article
650	0	4	_aAged
650	0	4	_aAlendronate _xtherapeutic use
650	0	4	_aBone Density _xdrug effects
650	0	4	_aBone Density Conservation Agents _xtherapeutic use
650	0	4	_aDenosumab _xtherapeutic use
650	0	4	_aDiphosphonates _xtherapeutic use
650	0	4	_aFemale
650	0	4	_aFollow-Up Studies
650	0	4	_aHumans
650	0	4	_aIbandronic Acid
650	0	4	_aImidazoles _xtherapeutic use
650	0	4	_aMiddle Aged
650	0	4	_aOsteoporosis, Postmenopausal _xdrug therapy
650	0	4	_aPostmenopause
650	0	4	_aTeriparatide _xtherapeutic use
650	0	4	_aZoledronic Acid
700	1		_aTsai, Joy N
700	1		_aJiang, Linda A
700	1		_aLee, Hang
773	0		_tBone _gvol. 98 _gp. 54-58
856	4	0	_uhttps://doi.org/10.1016/j.bone.2017.03.006 _zAvailable from publisher's website
999			_c26961352 _d26961352